1887

oa SA Pharmaceutical Journal - Impetigo : a review with a focus on retapamulin : review

 

Abstract

Nonbullous impetigo and bullous impetigo, caused by and , can be successfully treated with topical antibiotics. Retapamulin is a semi-synthetic pleuromutilin antibiotic with bacteriostatic properties against and . It prevents bacterial protein synthesis in multiple ways, and therefore reduces the risk of resistance developing. A twice-daily application of retapamulin for five days is effective in treating primary impetigo and secondarily infected traumatic lesions and dermatoses in patients older than nine months of age. The benefits of topical treatment include low systemic absorption, with less side-effects and a lower risk of resistance when compared to oral therapy. Serious adverse events have not been reported with the use of retapamulin. The most commonly reported adverse event has been local skin irritation. If lesions do not improve after 3-4 days of treatment with retapamulin, patients should consult their doctor to further investigate and eliminate the possibility of infection with non-susceptible strains.

Loading

Article metrics loading...

/content/mp_sapj/82/1/EJC167258
2015-01-01
2016-12-07
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error